The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis

Clin Liver Dis. 2023 May;27(2):413-427. doi: 10.1016/j.cld.2023.01.009. Epub 2023 Feb 26.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Disease spectrum varies from steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Currently, there are no approved medical therapies, and weight loss through lifestyle modifications remains a mainstay of therapy. Bariatric surgery is the most effective therapy for weight loss and has been shown to improve liver histology. Recently, endoscopic bariatric metabolic therapies have also emerged as effective treatments for patients with obesity and NAFLD. This review summarizes the role of bariatric surgery and endoscopic therapies in the management of patients with NAFLD.

Keywords: Bariatric endoscopy; Bariatric surgery; Endoscopic bariatric and metabolic therapies; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bariatric Surgery* / adverse effects
  • Humans
  • Liver / pathology
  • Liver Cirrhosis / complications
  • Liver Neoplasms* / pathology
  • Non-alcoholic Fatty Liver Disease* / etiology
  • Non-alcoholic Fatty Liver Disease* / surgery
  • Weight Loss